Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer

Author:

Jabbarzadeh Kaboli ParhamORCID,Chen Hsiao-Fan,Babaeizad Ali,Roustai Geraylow Kiarash,Yamaguchi Hirohito,Hung Mien-Chie

Funder

Ministry of Education

National Science and Technology Council

Ministry of Education - Singapore

China Medical University

Ministry of Health and Welfare

Publisher

Elsevier BV

Reference188 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J. Clin.,2021

2. Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy;Kaboli;Am. J. Cancer Res.,2021

3. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates;Jabbarzadeh Kaboli;Am. J. Cancer Res.,2022

4. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer;Ren;Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.,2016

5. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress;Jabbarzadeh Kaboli;Gene,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3